



Notification 6439

Implementation Date
10/5/2023

Category
HCPCS - Drugs & Biologicals

Topic
Louisiana Medicaid – Infliximab 10 mg, and biosimilars

What is changing?

We limit reimbursement of charges for infliximab, 10 mg, and its biosimilars to no more than 1 occurrence per 10 days, 2 occurrences within the last 41 days and the elapsed days between the last 2 occurrences is less than or equal to 31 days if the diagnosis is any of the following:

- Crohn's disease
- Ulcerative (chronic) pancolitis
- Ulcerative (chronic) proctitis
- Ulcerative (chronic) rectosigmoiditis
- Inflammatory polyps of colon
- Ulcerative colitis
- Psoriasis vulgaris

Language
English

Impacted Products

- Medicaid – Louisiana

Why is Humana making this change?

The limitations above are established by the FDA-approved package insert and prescribing information and the pharmaceutical compendia.